

European Society of Endocrinology's Embargo Policy in relation to the European Congress of Endocrinology (ECE) 2026

To ensure the integrity of scientific data and provide equal access to research findings, the European Society for Endocrinology (ESE) enforces a strict embargo policy on all accepted abstracts for the European Congress of Endocrinology.

This applies to both the abstract content itself, and any additional data or information presented at the Congress.

Certain abstracts selected for press releases by ESE may have an earlier embargo release time and this will be included on the specific press release (typically, 00:01 CEST on the day the abstract is being presented on).

Embargo timeline

All abstracts are under embargo until the official date and time of their scheduled presentation (oral or poster) at the Congress. Any press releases generated by the Author/s or their institution/s or company (in the case of a pharmaceutical company sponsored abstract) must honour this embargo policy.

The exception to this is for ESE's press releases on abstracts being presented at the Congress, which will have an embargo of 00:01 CEST on the day of the abstract's scheduled presentation (oral or poster) at the Congress.

Please note:

1. All accepted abstracts will be available on the Congress platform to registered delegates around one week before the Congress opening date which is **Saturday 9 May 2026**.
2. All accepted abstracts where an author has registered to attend ECE will be published as Open Access in a supplement of the [*European Journal of Endocrinology*](#), **several weeks after** the Congress has taken place. Abstracts, ePosters and other presentations will be available for registered attendees before the Congress via the online Congress platform.

Media and Public Disclosure

Authors, sponsors and media representatives must not publish, distribute, or promote abstract content (including title, data, or conclusions) before the embargo of the official date and time of their scheduled presentation (oral or poster) at the Congress lifts.

This includes:

- Press releases
- Social media posts
- Institutional websites
- Pre-recorded interviews or promotional materials

Permitted Activities BEFORE the embargo date/time

Authors may:

- Mention that their abstract has been accepted.
- Share the title and session information (without data or conclusions).
- Coordinate with the Congress Press Office for approval on any planned media outreach.

Embargo Violations

Breaches of this policy may result in:

- Withdrawal of the abstract from the programme.
- Loss of presentation privileges for the author or institution.
- Exclusion from future ECE Congresses.

Please contact media@ese-hormones.org if you have any queries.

Copyright

By submitting your abstract, Authors are assigning copyright of the abstract text to the European Society of Endocrinology and Oxford University Press (the publisher of the *European Journal of Endocrinology*).

Authors retain copyright on presentations and posters. The only copyright which transfers to ESE and remains with ESE even after the embargo period and in perpetuity is that of **published abstracts**.

If an abstract is rejected or withdrawn by the author before the withdrawal deadline, copyright will transfer back to the author.



Abstract may be reused at future conferences as encore abstracts if there is no pharmaceutical involvement. Authors must cite the EJE publication when reusing the abstract /content.



For other copyright queries once abstracts have been published in EJE, please email the editorial office: EJENDO.editorialoffice@theeditorialhub.com